Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.23 (-1.51%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.23 (-1.51%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.23 (-1.51%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.23 (-1.51%)
NASDAQ:SPRO

Spero Therapeutics - SPRO Stock Forecast, Price & News

$1.91
-0.01 (-0.52%)
(As of 11/28/2022 05:17 PM ET)
Add
Compare
Today's Range
$1.89
$1.95
50-Day Range
$0.82
$2.20
52-Week Range
$0.68
$16.30
Volume
264,920 shs
Average Volume
2.56 million shs
Market Capitalization
$66.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.33

Spero Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
231.6% Upside
$6.33 Price Target
Short Interest
Bearish
5.45% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.80
Upright™ Environmental Score
News Sentiment
1.35mentions of Spero Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$4.28 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.54) to ($1.50) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

111th out of 1,040 stocks

Pharmaceutical Preparations Industry

45th out of 509 stocks

SPRO stock logo

About Spero Therapeutics (NASDAQ:SPRO) Stock

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Receive SPRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SPRO Stock News Headlines

Earnings Outlook For Spero Therapeutics
Spero Therapeutics to Present Data at IDWeek 2022
This Infection-Fighting Biotech Is Recovering Nicely
Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK
Spero Therapeutics Rises
See More Headlines
Receive SPRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SPRO Company Calendar

Last Earnings
11/10/2021
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SPRO
Fax
N/A
Employees
146
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.33
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+231.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-89,760,000.00
Net Margins
-1,162.35%
Pretax Margin
-1,162.35%

Debt

Sales & Book Value

Annual Sales
$18.26 million
Book Value
$2.73 per share

Miscellaneous

Free Float
33,538,000
Market Cap
$66.98 million
Optionable
Optionable
Beta
0.78

Key Executives

  • Dr. Ankit  Mahadevia M.D.Dr. Ankit Mahadevia M.D. (Age 41)
    MBA, Co-Founder, Pres, CEO & Director
    Comp: $924.28k
  • Mr. Satyavrat Shukla C.F.A. (Age 50)
    CFO & Treasurer
    Comp: $788.84k
  • Ted Jenkins
    VP & Head of Investor Relations
  • Ms. Tamara Lynn Joseph L.L.M. (Age 59)
    Chief Legal Officer
  • Mr. James P. Brady
    Chief Human Resource Officer
  • Mr. Timothy Keutzer (Age 54)
    Chief Devel. Officer
  • Dr. Ian A. Critchley
    Head of Clinical Microbiology
  • Dr. Susannah Walpole Ph.D.
    Head of Clinical Operations
  • Dr. Angela Talley M.D.
    Sr. VP of Clinical Devel.
  • Dr. Kamal Hamed M.B.A.
    M.D., M.P.H., Chief Medical Officer













SPRO Stock - Frequently Asked Questions

Should I buy or sell Spero Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SPRO shares.
View SPRO analyst ratings
or view top-rated stocks.

What is Spero Therapeutics' stock price forecast for 2023?

4 analysts have issued 1 year price objectives for Spero Therapeutics' shares. Their SPRO share price forecasts range from $5.00 to $8.00. On average, they predict the company's stock price to reach $6.33 in the next year. This suggests a possible upside of 229.9% from the stock's current price.
View analysts price targets for SPRO
or view top-rated stocks among Wall Street analysts.

How have SPRO shares performed in 2022?

Spero Therapeutics' stock was trading at $16.01 at the start of the year. Since then, SPRO stock has decreased by 88.0% and is now trading at $1.92.
View the best growth stocks for 2022 here
.

Are investors shorting Spero Therapeutics?

Spero Therapeutics saw a increase in short interest in November. As of November 15th, there was short interest totaling 1,510,000 shares, an increase of 22.8% from the October 31st total of 1,230,000 shares. Based on an average daily trading volume, of 7,930,000 shares, the days-to-cover ratio is currently 0.2 days. Currently, 5.5% of the shares of the stock are sold short.
View Spero Therapeutics' Short Interest
.

When is Spero Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our SPRO earnings forecast
.

How were Spero Therapeutics' earnings last quarter?

Spero Therapeutics, Inc. (NASDAQ:SPRO) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.66) by $0.04. The business had revenue of $3.06 million for the quarter, compared to analysts' expectations of $3 million. Spero Therapeutics had a negative trailing twelve-month return on equity of 186.94% and a negative net margin of 1,162.35%. During the same period in the previous year, the business posted ($0.86) EPS.

What is Ankit Mahadevia, MD's approval rating as Spero Therapeutics' CEO?

27 employees have rated Spero Therapeutics Chief Executive Officer Ankit Mahadevia, MD on Glassdoor.com. Ankit Mahadevia, MD has an approval rating of 100% among the company's employees. This puts Ankit Mahadevia, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Spero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Editas Medicine (EDIT), SCYNEXIS (SCYX), Kadmon (KDMN), Aldeyra Therapeutics (ALDX), KushCo (KSHB), Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN).

When did Spero Therapeutics IPO?

(SPRO) raised $75 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

What is Spero Therapeutics' stock symbol?

Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."

Who are Spero Therapeutics' major shareholders?

Spero Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (5.50%), Anson Funds Management LP (4.20%), Vanguard Group Inc. (3.00%), Alphabet Inc. (2.54%), Murchinson Ltd. (2.17%) and Renaissance Technologies LLC (0.61%). Insiders that own company stock include Ankit Mahadevia, Aquilo Capital Management, Llc, Cristina Larkin and Sath Shukla.
View institutional ownership trends
.

How do I buy shares of Spero Therapeutics?

Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Spero Therapeutics' stock price today?

One share of SPRO stock can currently be purchased for approximately $1.92.

How much money does Spero Therapeutics make?

Spero Therapeutics (NASDAQ:SPRO) has a market capitalization of $67.33 million and generates $18.26 million in revenue each year. The company earns $-89,760,000.00 in net income (profit) each year or ($3.11) on an earnings per share basis.

How many employees does Spero Therapeutics have?

The company employs 146 workers across the globe.

How can I contact Spero Therapeutics?

Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The official website for the company is sperotherapeutics.com. The company can be reached via phone at (857) 242-1600 or via email at ir@sperotherapeutics.com.

This page (NASDAQ:SPRO) was last updated on 11/28/2022 by MarketBeat.com Staff